April 15, 2020 -- The EndPandemic National Data Consortium is about to expand by six life sciences and information technology companies.
The consortium was created in March as a way to bring companies together to accelerate the analysis of COVID-19 and SARS-CoV-2 research and reduce the time to find a cure.
The EndPandemic National Data Consortium's value proposition, strategic direction, charter, and business plan are being developed by Zaylan Associates and its partner Chrysalis Biomedical Advisors. The new organizations have pledged to bring their capabilities and global expertise to the consortium to facilitate clinical trial data sharing among and across biopharmaceutical, research, healthcare, and government sectors, as well as to create a continuously updated data repository that will generate insights for researchers worldwide.
The six new members are as follows: